Source: Allan Maurer, WRAL TECHWIRE, 12/28/17


What will the coming year hold for the biotech and life sciences industry in North Carolina? Based on the momentum we’re seeing at the end of this year, we should be in for a promising start to 2018.A strong market for initial public offerings: The biotech industry begins 2018 with some wind at its back, following a good year for IPOs – 46 in all for 2017, including North Carolina’s G1 Therapeutics, Argos Therapeutics and Dova Pharmaceuticals.  

For more of this story, click here.